Taiwan biotech companies will be presenting their latest achievements at international biotech conferences and exhibitions, including the American Association for Cancer Research (AACR), where OBI Pharma will present two therapeutic developments, and BiOptic, which will be making its first trip to Vietnam to promote its testing products.
The AACR Annual Meeting will be held in Orlando, Florida from April 14 to April 19. At the event, OBI Pharma will present preclinical data on the development of new drugs, including significant synergy between OBI-999 and the anti-PD1 antibody pembrolizumab in four different cancer models, and a chimeric antigen receptor T cell (CAR T) immunotherapy for Globo H (CAR T) immunotherapy for Globo H.
According to Dr Ming-Tian Lai, OBI-999 creates a tumour microenvironment that significantly enhances the function of pembrolizumab, and significantly enhances the anti-tumour effect in four allogeneic transplantation models of breast, gastric, colorectal and small cell lung cancer with Globo H and PD-1 expression. These findings provide strong support for the clinical study of the combination of OBI-999 and anti-PD-1/PD-L1 therapeutic strategy.
In addition, the results of BiOptic's CAR T-cell therapy (obi-R007) animal trial against Globo H showed strong and specific anti-tumour effects on Globo H-expressing tumour cells, which is a major step forward in the development of novel cellular therapies.
BiOptic will be exhibiting at Analytica Vietnam in Vietnam from 19 to 21 April, where it will showcase its shrimp virus test kit developed in collaboration with Torch Ammonium Biotechnology, as well as its new Qsep Ultra, a private label for in situ testing.
BiOptic's kit will include seven common shrimp diseases such as white spot disease (WSS), microsporidia (EHP), grass shrimp baculovirus (MBV), hepatopancreatic microvirus (HPV), decapod iridovirus (DIV1), acute hepatopancreatic necrosis (AHPND) and infectious subcutaneous and haematopoietic necrosis (IHHN).
However, the shrimp farming market has been threatened by new viruses, such as acute hepatopancreatic necrosis, which once caused a serious loss of nearly 50% in the annual production of Vietnam and other major shrimp farming countries. This is why the adoption of BiOptic's biotechnology platform with the shrimp disease test kit can be used by farmers as a tool to prevent and control shrimp diseases and help the industry grow steadily, said Eric Tsai, Chairman of BiOptic.
